|
Characteristic
|
Emirati validation cohort (n = 554)
|
Framingham study cohort* (n = 5251)
|
P-value†
|
|---|
|
Age (years), mean (SD)
|
48.0 (12.8)
|
49.0 (NA)
| |
|
Men, n (%)
|
249 (44.9)
|
2439 (46.4)
|
0.502
|
|
Blood pressure, n (%)
|
|
Normal and prehypertension
|
408 (73.7)
|
3558 (67.7)
|
< 0.001
|
|
Stage 1 HTN
|
116 (20.9)
|
1095 (20.9)
| |
|
Stage 2 HTN
|
30 (5.4)
|
598 (11.4)
| |
|
TC, mmol/L, n (%)
|
|
< 5.17
|
298 (53.8)
|
1996 (38.0)
|
< 0.001
|
|
5.17–6.18
|
166 (30.0)
|
1879 (35.8)
| |
|
≥ 6.20
|
90 (16.2)
|
1376 (26.2)
| |
|
HDL-C, mmol/L, n (%)
|
|
≤ 1.53
|
482 (87.0)
|
3829 (72.9)
|
< 0.001
|
|
≥ 1.55
|
72 (13.0)
|
1422 (27.1)
| |
|
Smoking history, n (%)
|
102 (18.4)
|
2045 (38.9)
|
< 0.001
|
|
Diabetes mellitus, n (%)
|
0 (0.0)‡
|
234 (4.5)
|
< 0.001
|
|
Observed hCHD events, n (%)
|
26 (4.7)
|
273 (5.2)
| |
- NA, not available; HTN, hypertension; TC, total cholesterol; HDL-C, high-density lipoprotein-cholesterol; hCHD, hard coronary heart disease; SD, standard deviation; FRS, Framingham risk score
- *Data retrieved from D’Agostino et al. [10]
- †P-values for categorical variables were calculated using Fisher’s exact test (2-tailed)
- ‡The FRS hCHD model is not intended for patients with diabetes, therefore excluded from the study
